RESEARCH ARTICLE

Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotopes

Bence Szikora¹, László Hiripi², Balázs Bender³, Imre Kacskovics¹,³, Attila Iliás¹ *

¹ Department of Immunology, ELTE Eötvös Loránd University, Budapest, Hungary, ² Department of Animal Biotechnology, National Agricultural Research and Innovation Centre, Gödöllő, Hungary, ³ ImmunoGenes-ABS Ltd, Budakeszi, Hungary

* attila.ilias@ttk.elte.hu

Abstract

Despite the increasing importance of rabbit as an animal model in pharmacological studies like investigating placental transfer of therapeutic IgGs, little is known about the molecular interaction of the rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG molecules. We analyzed the interactions of the rabbit and human FcRn with rabbit and human IgG isotopes using surface plasmon resonance assay. Similar to FcRn of other species, rabbit FcRn functions in pH-dependent manner, as it binds IgGs at pH 6.0, but no binding occurs at pH 7.4. We also showed that rabbit FcRn binds rabbit IgG and human IgG1 with nearly identical affinity, whereas it has stronger interactions with the other human IgG isotopes. The similar affinity of rabbit IgG and human IgG1 for rabbit FcRn was confirmed by in vitro FcRn-mediated recycling assay. These data verify that rabbit is an appropriate animal model for analyzing the pharmacokinetics of human therapeutic monoclonal antibodies.

Introduction

The neonatal Fc receptor, FcRn is a heterodimer consisting of an MHC-I like α-chain and β2-microglobulin (β2m) [1]. FcRn plays an important role in the transcytosis of maternal IgG to the fetus and in maintaining IgG and albumin homeostasis in adult [2], as well as in antigen presentation by professional Ag presenting cells in case of Ag-IgG immune complexes [3–5].

FcRn functions in pH-dependent manner, as it binds IgG at slightly acidic pH (pH 5.5–6.0) whereas this interaction is negligible at around neutral pH (pH 7.2–7.4) [6–8]. The 2:1 FcRn: IgG binding stoichiometry, i.e. two FcRn molecules bind one IgG at independent sites was first proposed by FcRn:Fc co-crystal structures [9–11] and was further confirmed by gel filtration studies in solution [12–14], and recently, by surface plasmon resonance measurements [15]. However, FcRn can also form 1:1 complexes with the Fc region of IgG when assayed under non-equilibrium conditions [16].

In rabbit, it was found decades ago that the transfer of maternal IgG and at a lower extent, albumin occurs across the rabbit fetal yolk sac membrane (YSM) from the maternal uterine lumen to the fetus [17]. Furthermore, human IgG (hIgG) injected into the maternal circulation...
was also transported well to the rabbit fetus [17] indicating that rabbit FcRn (rbFcRn) binds efficiently hlgG. Low level antibody transfer could be observed during early gestation, prior to gestation day (GD) 8 due to the incomplete tight junctions of the bilaminar yolk sac membrane [18], however, no or only limited antibody transport could be detected during the period of yolk sac inversion (GD 9–13). Once inversion is completed (around GD 15), then IgG transport starts up through FcRn-mediated transcytosis, and the rate continuously increases with the progression of gestation [19–21]. Accordingly, the available data regarding the placental transfer of human therapeutic monoclonal antibodies (mAb IgGs) and Fc-containing biopharmaceuticals, similar to endogenous maternal IgG, indicate low fetal exposures until inverted yolk sac placenta is evolved, and near maternal level is reached at the end of gestation (GD 29–31) [19, 21–23].

The blood clearance of rabbit IgG (rbIgG) and hlgG was also investigated in rabbits and it was found that the half-life of rbIgG and a hlgG preparation was quite similar, around 6 and 5 days, respectively, which indicates that the FcRn-mediated salvage mechanism in rabbits works for hlgG, as well [24–26]. The similar half-lives of rbIgG and hlgG also suggest that rbFcRn binds similarly these IgGs, as IgG half-life depends on its binding affinity to FcRn [27].

Since then, it was clearly demonstrated that FcRn is highly expressed in the apical plasma membrane of the brush border’s endodermal cells of rabbit fetal yolk sac membrane (YSM) and in the placental capillary endothelial cells indicating that maternal IgG transport through the placenta is fulfilled by FcRn [28]. In addition, based on the highly conserved FcRn-IgG contact residues the pH-dependent IgG binding of FcRn was demonstrated in IgG-binding assay by Western blot using rbIgG and yolk sac lysates of rabbit fetuses [28].

Despite being an important animal model in pharmacological studies, like investigating placental transfer of therapeutic mAbs and Fc-containing biopharmaceuticals [19], the interactions of rbFcRn with rbIgG and hlgG isotypes at molecular level have not been analyzed. Therefore, we generated and purified rbFcRn and analyzed first its pH-dependent binding of rbIgG and hlgG isotypes by surface plasmon resonance assay, which provided detailed kinetic data of the interaction. Moreover, these data were further validated in vitro by FcRn-mediated recycling assay using rabbit macrophages.

**Materials and methods**

**Amplification of soluble rbFcRn α-chain and rabbit β2-microglobulin (rbβ2m) cDNAs**

Total RNA purification from 50 µg rabbit spleen was carried out using RNeasy Plus Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. 200 ng of DNase-treated total RNA was used for the first strand cDNA synthesis (High Capacity cDNA Reverse Transcription Kit; Life Technologies, Carlsbad, CA, USA). Negative control reverse transcription reactions were conducted to confirm no genomic DNA contamination in the RNA preparation.

The spleen cDNA sample was used as PCR templates to amplify the full-length coding region of rbβ2m and the truncated, soluble FcRn α-chain (lacking the transmembrane and the cytoplasmic domains) cDNAs, respectively, using gene specific primers. Specific oligonucleotides were used to amplify rbFcRn α-chain cDNA (forward: 5’ – ATCAGAATTCTCCTATAATATGGGGGCCGCCCCGGCTT–3’; reverse: 5’ – ATCAGAATTCTAATGATGATGATGATGATGATGACGACCTTTCGATCGCCGCGCAACGACCGCT–3’). EcoRI linker and insect Kozak sequence (5’ – CCTTAAAATATG–3’) was also added to the 5’ end of the forward oligo, while EcoRI linker, 6xHis tag and Factor Xa recognition sequence (5’ – ACGACCTTTCGAT–3’) was added to the 5’ part of the reverse oligonucleotide. rbβ2m was amplified with specific
oligonucleotides (forward: 5′ - ATCAGGATCCCCCTATAATATGTGGCGCTCCGTCTTGGG - 3′; reverse: 5′ - ATCAGGATCTCTGATTAGTAAATCTGAT - 3′). Both oligonucleotide primers contained BamHI linker sequence, furthermore the forward oligo harbored insect Kozak linker sequence, as well.

PCR reactions were performed in a 20-μl reaction mix (RedTaq ReadyMix; Sigma-Aldrich, St. Louis, MO, USA) with the condition of a 5 min denaturation at 94°C followed by 32 cycles of 94°C for 30 sec, 59°C for 45 sec, and 72°C for 30 sec, and a final extension at 72°C for 3 min. DNA fragments obtained by RT-PCR were purified from agarose gels using a QIAquick Gel extraction kit (Qiagen, Hilden, Germany) and sequenced directly.

**Construction of the baculovirus expression vector**

To co-express soluble rFcRn and rβ2m in Sf9 cells the cDNA of rFcRn α-chain was inserted into the EcoRI site in the baculovirus transfer vector, pAcUW51 under the control of the p10 promoter. The rβ2m cDNA was then inserted into the BamHI site under the control of the polyhedrin promoter of pAcUW51 containing rFcRn α-chain cDNA. Orientation of both inserts was verified by restriction analysis and by sequencing.

**Expression and purification of soluble rFcRn**

Recombinant baculoviruses carrying the cDNAs of the soluble rFcRn α-chain and rβ2m were generated by using the BaculoGold Transfection Kit (BD Biosciences Pharmingen, Franklin Lakes, NJ, USA) according to the manufacturer’s instructions. Then, Sf9 cells were cultured and infected by recombinant viruses. Recombinant rFcRn was purified from supernatants of virus infected cells by using Ni-NTA chromatography (His-Select Nickel Affinity Gel, Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s protocol. Expression level and purity of the recombinant protein was confirmed by 15% SDS-PAGE followed by either Coomassie staining or Western blotting. Mouse anti-His tag antibody (AbD Serotec, Kidlington, UK) as the primary (500x) and HRP-conjugated goat anti-mouse IgG (Southern Biotech, Birmingham, AL, USA) as the secondary antibody (10,000x) were used for immuno-detection. The yield of the rFcRn expression was approximately 5 mg/l (5 mg purified protein per 1 liter cell culture supernatant).

**Size-exclusion chromatography**

The aggregations of the purified FcRn samples were analyzed by size-exclusion chromatography (SEC). Agilent-1100 chromatographic system (Agilent Technologies, Santa Clara, CA, USA) equipped with a UV detector was employed with a Yarra SEC-3000 column (l: 300mm, id.: 4.6mm; Phenomenex, Torrance, CA, USA). Mobile phase composition was 50 mM phosphate buffer, pH 6.8 supplemented with 0.3 M potassium chloride and the volumetric rate of mobile phase was 0.35 ml/minute. Column temperature was 30°C.

Samples were diluted to 1 mg/ml protein concentrations in PBS-T buffer, pH 7.4 (10 mM Na-phosphate, 150 mM NaCl, 0.005% Tween 20). 5 μl sample solutions were injected for analysis and monitored at 215 nm. Molecular weight of the detected sample components was calculated using calibration curves. A molecular weight standard solution (ALO-3042, Phenomenex, Torrance, CA, USA) that contains reference proteins from 17 kDa to 670 kDa and 1 mg/l BSA solution as an additional reference was used for establishing calibration curves and for testing the resolution of chromatographic system. The calibration curves were linear in the range studied. The detected components were identified according to the molecular weight calculated and the results were expressed as the purity (percentage area) of the principal (FcRn) component.
Surface plasmon resonance (SPR) measurements

The preparation of the GLC sensor chip and the immobilization procedure by amine coupling were performed according to the manufacturer’s instructions. Briefly, GLC chip was inserted to the ProteOn XPR36 biosensor instrument (Bio-Rad, Hercules, CA, USA), and was initialized by 50% glycerol. The immobilization procedure was carried out in the vertical orientation at a flow rate of 30 μl/min in PBS-T buffer, pH 7.4 (10 mM Na-phosphate, 150 mM NaCl, 0.005% Tween 20) at 25°C. Thereafter, 0.2 M EDAC and 0.05 M sulfo-NHS were mixed in 1:1 ratio and the solution was injected immediately with 2 min of contact time in order to activate the chip surface. This was followed by an immediate injection of 150 μl of ligand solutions containing 10 μg/ml of rbFcRn and human FcRn (the latter, similar to our rbFcRn, is a soluble form of hFcRn, which was a kind gift from Sally E. Ward, UT Southwestern Medical Center, Dallas, TX, USA), or 2 μg/ml of rbIgG (ATG-Fresenius, Fresenius Biotech, Bad Homburg, Germany) and hlgG1 (Omalizumab, Genentech, San Francisco, CA, USA), respectively, in 10 mM Na-acetate buffer, pH 5.0, for 5 min. For detecting background responses, a control channel without any protein was prepared following the same procedure. Finally, the remaining activated carboxyl groups on the chip surface were neutralized by the injection of 150 μl of 1 M ethanolamine-HCl, pH 8.5 for 4 min. This resulted in the immobilization of approximately 1200 and 1600 RU in case of rbFcRn and hFcRn, respectively, and concerning rbIgG and hIgG1 the immobilization levels were approximately 1900 and 2100 RU, respectively.

Binding experiments were performed with a continuous flow (100 μl/min) of PBS-T buffer, at pH 6.0 or pH 7.4 allowing for a contact time of 2 min at 25°C. Five different concentrations (8.34, 16.7, 33.3, 66.7 and 133 nM) of rbIgG (ATG-Fresenius, Fresenius Biotech, Bad Homburg, Germany) and hlgG isotypes (hlgG1: Omalizumab, Genentech, San Francisco, CA, USA; hlgG2, hlgG3, hlgG4: Abcam, Cambridge, UK) were injected in the horizontal orientation of channels over immobilized FcRn molecules, respectively, and running buffer, PBS-T was injected simultaneously to the first channel. Similarly, when IgG molecules were immobilized on the chip surface, five different concentrations (37.5, 75, 150, 300 and 600 nM) of rbFcRn and hFcRn were injected. After the measurement, the chip surface was regenerated by a 30 sec injection of 0.1 M Tris, pH 8.0 to remove any remaining analyte.

All binding sensorgrams were collected and processed using the integrated ProteOn Manager software, version 3.1.0.6 (Bio-Rad, Hercules, CA, USA). The curves were corrected by subtracting the non-specific binding responses obtained from control channel. Then, the kinetic analyses were performed by the BIAevaluation software, version 4.1 (Biacore, GE Healthcare, Little Chalfont, United Kingdom). Binding curves were fit to either Langmuir 1:1 interaction or heterogeneous ligand model supposing that there are two classes of non-interacting binding sites. The equilibrium dissociation constants or affinity constants were calculated from the directly estimated association and dissociation rate constants (Langmuir model: \( K_D = k_d/k_a \) or heterogeneous ligand model: \( K_{D1} = k_{d1}/k_{a1} \) and \( K_{D2} = k_{d2}/k_{a2} \)) and in case of the latter model the percentage of the total response according to each class of binding sites (\( f_1 \) and \( f_2 \)) were also estimated.

Fluorescent IgG preparation and FcRn-mediated recycling assay in rabbit macrophages

rbIgG and hlgG1 were conjugated to Alexa Fluor 488 (A488) using the Alexa Fluor 488 carboxyl acid succinimidy l ester labeling kit (Molecular Probes, Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Labeled proteins were separated from free dye using Vivaspin 2 centrifugal concentrator (10,000 MWCO PES; Sartorius, Dublin, Ireland). Protein concentration, and degree of labeling were determined by
spectrophotometry using Nanodrop 2000 instrument (lIgG1: 5.5 mg/ml, conjugation rate: 0.8, rblIgG: 5.9 mg/ml, conjugation rate: 1.9).

Two females of New Zealand White rabbit (S&K-LAP Ltd, Kartal, Hungary) were used in this study. Animals were kept under standard light-dark cycle (06.00–18.00 h) at 19°C with food and water available ad libitum and caged separately. All the treatments of animals (rabbits) in this research followed by the guideline of the Institutional Animal Care and Ethics Committee at ImmunoGenes-ABS Ltd that operated in accordance with permission XIV-I-001/2086-4/2012 issued by the Food Chain Safety and Animal Health Directorate of the Government Office of Pest County, Hungary. All surgery was performed under ketamine/xyazine anesthesia. The method used for euthanasia: concussion under anesthesia and all efforts were made to minimize suffering.

Rabbit macrophages were isolated from the peritoneum of a New Zealand White rabbit 3 days after i.p. injection of 40 ml 3% Brewer thioglycol medium based on a standard protocol [29]. Red blood cells were lysed in hypotonic buffer (45 mM NH₄Cl, 2.5 mM KHCO₃, 0.05 mM Na₂EDTA, pH 7.2). 1 μ-slide 8-well plates (Ibidi, Martinsried, Germany) were coated with 100 ng/ml fibronectin, and 3 × 10⁵ cells were added in 300 μl RPMI-1640 medium supplemented with 10% fetal bovine serum and allowed to adhere for O/N at 37°C in a CO₂ incubator. Then, the non-adherent cells were washed out and the cells were pulsed by adding 300 μl 20 μg/ml fluorescently labeled (A488) rblIgG or lIgG1 to the cells for 20 minutes in Hank’s buffer, pH 6.0 (143 mM NaCl, 1 mM Na₂SO₄, 5 mM KCl, 1 mM Na₂PO₄, 0.5 mM MgCl₂, 1 mM CaCl₂, 5 mM glucose, 10 mM HEPES). After washing twice, the chase was started by replacing buffer to Hank’s buffer, pH 7.4 lacking fluorescent probes, and the amount of labeled antibodies accumulated in the cells was visualized at 0 and after 30 minutes by Olympus Fluoview500 inverted Laser Scanning Confocal Microscope (Olympus-Europe, Hamburg, Germany; at 20x magnification). For image processing and evaluation Fiji software [30] was used. Based on the bright field image a region of interest was drawn around individual well-adherent cells and due to the different labeling efficiency of rblIgG and lIgG1 the median pixel intensity was recorded. Minimum of 30 cells were analyzed from each sample, but cells with large amount of saturated pixels were eliminated from analysis. The fluorescence signal in each image plane was corrected for background (by subtracting the median fluorescence intensity of five different cell-free area). Paired two-sample t-test was used for the statistical analyses.

Results and discussion
Amino acid residues in FcRn-IgG interaction
The truncated form of the rFcRn α-chain and the rβ2m were PCR cloned. The cDNA sequences showed 100% identity with the published rFcRn α-chain sequence [28] and the annotated rβ2m sequence (XM_008269078). At protein level, Asn was found at position 95, as well as at position 97 in the only published sequence of rβ2m [31], whereas NCBI reference sequence analysis (XP_008267300.1) and our cDNA clone (the sequence was deposited into GenBank: KT151665) predicted Asp at both positions.

The sequence comparisons show high identity between human (GenBank: ARO48560) and rabbit (Genbank: AEN74950) [28] variants of FcRn α-chain (72%), human (GenBank: CAG33347) and rabbit (GenBank: KT151665) β2m (74%), as well as human (lIgG1 GenBank: P01857, hIgG2 GenBank: P01859, hIgG3 GenBank: P01860, hIgG4 GenBank: P01861) and rabbit IgG (GenBank: P01870) isotypes (69–71%) querying the NCBI Reference Sequences database with Blastp. There is one potential N-linked glycosylation sites (N-X-S or N-X-T; where X is any amino acid except proline) at position 102 in both FcRn α-chain sequences (numbering is based on the human sequence) and another one at position 297 in CH2 domain
of all human and rabbit IgG isotype sequences (numbering is based on the hIgG1 sequence) (Fig 1).

Focusing on the important residues of the FcRn-IgG interaction in the hFcRn and rbFcRn α-chain sequences based on a crystallography analysis of a rat FcRn-heterodimeric Fc complex [10], we found that these amino acids are highly conserved between the two species. Only two conservative substitutions can be observed, Asp instead of Glu at position 116 and Glu instead of Asp at position 130 (amino acid numbering follows the human sequence) in rbFcRn α-chain comparing with human sequence (Table 1).

Between the two residues in rbβ2m sequence playing role in the interaction with IgG one is conserved (Gln2 in both species), while Ile at position 1 in the hβ2m is replaced by Val in the rabbit sequence which is considered to be also a conservative substitution (Table 1).
Analyzing the sequences of human and rabbit IgG isotypes no amino acid changes can be observed in the sequences of rblG, hlgG1, hlgG2 and hlgG4 concerning the residues involved in the interaction with FcRn α-chain, moreover, only two residues vary in hlgG3, Arg can be found at position 435 instead of His, and Phe at position 436 instead of Tyr (Table 1).

However, both residues are replaced in rblG at positions being important in the interaction with β2m, all human IgG isotypes contains Thr and Lys at positions 307 and 288, while Pro and Arg occur in these positions of the rblG sequence, respectively.

Altogether, we can conclude that except T307P replacement in the rblG sequence all the contact residues being involved in FcRn-IgG interaction are conserved between human and rabbit variants suggesting similarities in their pH-dependent mechanism of action.

**Expression of the soluble form of rbFcRn**

The cDNAs of truncated rbFcRn α-chain and rbβ2m were co-expressed in Sf9 insect cells and the self-assembled soluble recombinant rbFcRn was purified from the cell supernatants using Ni-NTA chromatography. The expression level was confirmed by SDS-PAGE visualized by Coomassie staining where two bands appeared, an approximately 28 kDa band referring to FcRn α-chain and another about 12 kDa band to the β2m, similarly to the soluble hFcRn (Fig 2A). By using anti-His-tag-specific monoclonal antibody in Western blot experiments the rbFcRn and hFcRn α-chains containing 6xHis-tag could be detected around 28 kDa (Fig 2B).

The purity of the FcRn molecules, as well as the rblG and hlgG samples was analyzed by SEC which revealed that the purity of hlgG1 and rblG, as well as hFcRn was >95%, while the rbFcRn preparation was around 90%, but it did not contain any higher-order aggregates (Fig 2C–2F). Some residual molecule (at 8.845 and 9.381 mins of retention time, altogether approximately 9%), potentially bovine serum albumin (BSA) remained in the preparation after purification (Fig 2C), as these fractions ran equivalently with BSA in the molecular weight standard and the ratio of these components could be increased by adding extra BSA. However, as BSA does not react with IgGs, it did not influence our further analyses.

**pH-dependence and isotype-specific differences of IgG binding**

Detailed kinetic data of the interaction of human, cynomolgus monkey, bovine, rat and mouse FcRn with IgG isotypes from different species are available [11, 15, 34–37], however, to date no data has been reported concerning the kinetics of the rbFcRn interaction with rblG and hlgG isotypes.

---

### Table 1. FcRn and IgG residues known to be involved in FcRn–IgG interaction.

| α-chain residue | Human Fc residue | Rabbit Fc residue | Human IgG | Rabbit IgG |
|-----------------|------------------|------------------|-----------|-----------|
| 115             | E                | E                | 310       | H         | H         | H         | H         |
| 116             | E                | D                | 311       | Q         | Q         | Q         | Q         |
| 130             | D                | E                | 435       | H         | H         | R         | H         | H         |
| 131             | W                | W                | 253       | I         | I         | I         | I         |
| 135             | L                | L                | 436       | Y         | Y         | F         | Y         |

β2m residue

| Numbering is based on the hFcRn, hβ2m and the hlgG1 sequences, respectively. |
|-----------------|------------------|------------------|
| 1               | I                | V                | 307       | T         | T         | T         | T         |
| 2               | Q                | Q                | 288       | K         | K         | K         | K         | R         |

https://doi.org/10.1371/journal.pone.0185662.t001
FcRn experts apply two different SPR experimental set-ups, either FcRn or IgG molecules are immobilized on the sensor chip surface. Accordingly, depending on which molecule is immobilized on the surface the evaluation methods, the determined kinetic parameters can be different. When FcRn is immobilized and IgG molecules are injected as analytes, the FcRn-IgG interaction can be characterized only by complex kinetics supposed two classes of non-interacting binding sites described by heterogeneous ligand model [11, 13, 35, 38–40]. In opposing assay orientation, when IgG is coupled to the surface and FcRn molecules are injected over it, the interaction can be described by simple Langmuir 1:1 binding model [13, 15, 37]. Examples for both set-ups can be found in the literature, however, to date there is no consensus concerning the accepted orientation, immobilization and evaluation methods [15, 37]. Therefore, the IgG binding of rbFcRn was analyzed using both experimental set-ups in our SPR experiments, either rbFcRn and hFcRn or rbIgG and hlgG1 molecules were immobilized.

**Immobilization of FcRn.** Soluble forms of rbFcRn and hFcRn were covalently immobilized onto the chip surface, and dilutions of rbIgG and hlgG isotypes were injected over them. Our results demonstrated that rbFcRn, similarly to other FcRn orthologues binds IgG in strictly pH-dependent manner, as it interacts with rbIgG, as well as hlgG isotypes at pH 6.0 (binding of rbIgG and hlgG1 at 133 nM concentration are shown on Fig 3A and 3B), while no binding could be detected at pH 7.4 using rbIgG (Fig 3A), hlgG1 (Fig 3B), hlgG2, hlgG3 and hlgG4. FcRn was used as a control, and we measured very similar binding kinetics in the presence of either rbIgG or hlgG isotypes at pH 6.0 and also at pH 7.4.

In an earlier study, it was suggested that in rabbit, binding and selective transcytosis of IgG through rabbit visceral yolk sac (VYS) did not require acidic compartment and thus, rbFcRn binds IgG in pH-independent manner [41]. In contrast to this observation our previous study demonstrated that the binding of IgG to rbFcRn was pH-dependent using an *in vitro* IgG-
binding assay with yolk sac lysates of rabbit fetuses [28]. In accordance with the latter finding our SPR measurements clearly demonstrated that rbFcRn interacts with rbIgG and hIgGs at pH 6.0 and no binding occurs at pH 7.4.

Injecting a series of concentrations of rbIgG and hIgG isotypes over rbFcRn and hFcRn immobilized on the chip surface, the kinetic parameters of IgG binding of both rbFcRn and hFcRn could be determined. Fits of sensorgrams were performed using the heterogeneous ligand model postulating two or more populations of non-interacting binding sites [11, 13, 38] (Fig 4A and 4B).

By means of this model, a high affinity constant, $K_D^1$ when two FcRn molecules bind one IgG and a low affinity constant, $K_D^2$, referring to 1:1 FcRn:IgG stoichiometry can be distinguished (Table 2).

Comparing the high affinity constants ($K_{D1}$) of the interactions we found that rbFcRn binds hIgG3 and hIgG4 with the highest affinity (2.57 and 3.86 nM, respectively), hIgG2 with a slightly lower affinity, 7.46 nM, which interactions were apparently stronger than that of hIgG1 (12.9 nM) and rbIgG (20.3 nM). The low affinity constants ($K_{D2}$) of rbIgG, hIgG4 and hIgG3 were almost identical, 49.3, 53.5 and 59.2 nM, respectively, while hIgG1 and hIgG2 showed weaker (71.9 and 106 nM, respectively) interactions.

As our SPR data revealed, rbFcRn showed almost identical $K_D$ values for hIgG1 and slightly higher affinity for other hIgG isotypes than for rbIgG. The stronger interaction with IgG from another species is not a unique feature of rbFcRn, because similar cross-species binding differences were observed concerning mouse, as well as bovine FcRn, which showed also higher affinity for hIgG1 than for their own, mouse [36, 40, 42, 43] and bovine IgG isotypes [35], respectively.

Being aware of kinetic data of the interaction of rbFcRn with hIgG isotypes it would be interesting to interpret the placental transport of human therapeutic mAbs and Fc-containing biopharmaceuticals performed previously in rabbits.
Table 2. Kinetic parameters of the interaction of immobilized rbFcRn and hFcRn with rbIgG and hlgG isotypes at pH 6.0.

|                  | rbFcRn       | hFcRn       |
|------------------|--------------|-------------|
|                  | $K_{D1}$ (M) $\times 10^{-3}$ | $f1$ (%) | $K_{D2}$ (M) $\times 10^{-3}$ | $f2$ (%) | $K_{D1}$ (M) $\times 10^{-3}$ | $f1$ (%) | $K_{D2}$ (M) $\times 10^{-3}$ | $f2$ (%) |
| rbIgG            | 20.3 ± 2.21  | 68.4        | 49.3 ± 1.78  | 31.6        | 6.58 ± 0.12     | 77.0    | 15.9 ± 0.27     | 23.0    |
| hlgG1            | 12.9 ± 1.83  | 28.8        | 71.9 ± 15.7  | 71.2        | 9.99 ± 0.43     | 42.4    | 57.2 ± 3.05     | 57.6    |
| hlgG2            | 7.46 ± 1.41  | 84.3        | 106 ± 31.5   | 15.7        | 5.43 ± 0.26     | 89.2    | 34.7 ± 0.68     | 10.8    |
| hlgG3            | 2.57 ± 0.52  | 49.9        | 59.2 ± 7.25  | 50.1        | 6.06 ± 0.25     | 74.8    | 17.4 ± 0.50     | 25.2    |
| hlgG4            | 3.86 ± 0.79  | 89.8        | 53.5 ± 20.0  | 30.5        | 2.36 ± 0.14     | 92.1    | 20.2 ± 1.01     | 7.9     |

The $K_D$ values (mean ± S.E.) were calculated from the estimated association and dissociation rate constants ($K_{D1} = k_{a1}/k_{d1}$) and ($K_{D2} = k_{a2}/k_{d2}$) using heterogeneous ligand model during the fitting procedure ($n = 2–3$).
efficiently, since 3-fold difference could be observed in high affinity constants (7.46 nM for hlgG2 and 20.3 nM for rblG), however, almost the opposite interaction was measured concerning the low affinity constants (106 nM for hlgG2 and 49.3 nM for rblG).

Analyzing the high affinity interactions of hFcRn with rblG and hlgG isotypes only little difference could be seen in affinities: hlgG4 has the highest affinity (2.36 nM), rblG, hlgG2 and hlgG3 bind similarly to hFcRn (6.58, 5.43 and 6.06 nM, respectively), whereas the interaction is slightly weaker concerning hlgG1 (9.99 nM). The low affinity constants of rblG and hlgG3 showed the lowest (15.9 and 17.4 nM), hlgG1 showed the highest value (57.2 nM), and the other K_D values were in between (20.2 nM for hlgG4 and 34.7 nM for hlgG2). These data agree well with K_D values obtained by others also with hlgG isotypes and immobilized hFcRn in SPR measurements [11, 38, 39].

Polyclonal rblGs so-called anti-thymocyte globulin (ATG) preparations (like ATG-Fresenius by Fresenius Biotech, Bad Homburg, Germany and Thymoglobulin by SanoGi Genzyme, Cambridge, MA, USA) are extensively used as immunosuppressant agents in clinical applications, mainly in the field of human transplantation [45]. Our SPR results revealed that rblG binds to hFcRn as effective as hlgG isotypes, therefore it can successfully compete with endogenous IgG and can be protected from the degradation by FcRn in human which can explain the success of rabbit anti-thymocyte globulin therapy.

**Immobilization of IgG.** As hlgG1 is used mostly in therapeutic mAbs or Fc-fusion proteins, we have focused this human isotype along rblG in the next experiment. When rblG and hlgG1 were immobilized on the chip surface, and rblFcRn and hFcRn were injected over, similar results were obtained what was observed at reverse orientation, namely, rblFcRn binds rblG and hlgG1 in a strictly pH-dependent manner (Fig 3C and 3D).

Next, rblFcRn and hFcRn were injected at varying concentrations (37.5 to 600 nM) over the surface in order to determine the kinetic parameters of the interaction. This experimental set-up gives the possibility to apply the Langmuir 1:1 binding model in kinetic analyses instead of complex kinetics e.g heterogeneous ligand model [13, 15, 37] (Fig 4C and 4D).

Kinetic parameters were determined and data showed that rblFcRn-rblG and rblFcRn-hlgG1 interactions have nearly identical affinity (1.48 and 1.19 nM, respectively), while hFcRn binds rblG with a slightly lower (2.46 nM) and hlgG1 with even lowest affinity (4.30 nM) (Table 3).

These results are in accordance with the parameters obtained at reverse orientation, namely rblFcRn binds hlgG1 similarly to rblG. This explains why FcRn-mediated salvage mechanism and maternal IgG transport in rabbits function efficiently for intravenously injected hlgG1, as previously described [17]. In addition, this transplacental transport is supposed to be proportional to the amount of hlgG1 found in the serum. This is important assumption in regard to rabbits that are widely used as animal model in transplacental studies of human therapeutic monoclonal antibodies (IgG).

In order to validate our SPR results, the interaction of rblFcRn with rblG and hlgG1 was investigated *in vitro* by FcRn-mediated recycling assay using rabbit macrophages.

| Table 3. Kinetic parameters of the interaction of immobilized rblG and hlgG1 with rblFcRn and hFcRn at pH 6.0. |
|-----------------------------------------------|
| k_a (M⁻¹·s⁻¹) x 10⁶ | k_d (s⁻¹) x 10⁻⁴ | K_D (M⁻¹) | k_a (M⁻¹·s⁻¹) x 10⁶ | k_d (s⁻¹) x 10⁻⁴ | K_D (M⁻¹) |
|-----------------|-----------------|-----------|-----------------|-----------------|-----------|
| rblG            | 2.67 ± 0.17     | 3.94 ± 0.13 | 1.48 ± 0.14     | 3.23 ± 0.31     | 7.92 ± 0.34 | 2.46 ± 0.34 |
| hlgG1           | 3.27 ± 0.16     | 3.90 ± 0.14 | 1.19 ± 0.10     | 1.38 ± 0.10     | 5.92 ± 0.13 | 4.30 ± 0.41 |

The K_D values (mean ± S.E.) were calculated from the estimated association and dissociation rate constants (K_D = k_d/k_a) using Langmuir 1:1 binding model during the fitting procedure (n = 2~3).

https://doi.org/10.1371/journal.pone.0185662.t003
FcRn-mediated IgG recycling assay using rabbit macrophages

FcRn-mediated IgG protection primarily takes place in capillary endothelial cells and also in hemopoietically-derived phagocytic cells, like macrophages [46]. Accordingly, significant FcRn expression could be detected in bone-marrow-derived macrophages in mice [4, 46], as well as in peritoneal macrophages in rabbits [28].

Rabbit macrophages isolated from the peritoneum of a New Zealand White rabbit were then used for FcRn-mediated recycling experiments. Isolated cells were plated and allowed to adhere. After removal of non-adherent cells the pulse step was started at pH 6.0 by adding fluorescently labeled rbIgG or hlIgG to the cells which lasted for 20 minutes. Pulsing at slightly acidic pH, due to FcRn-IgG interaction cells can only take up IgG via fluid-phase pinocytosis, Fcγ-receptor- or perhaps even FcRn-mediated process, but IgG cannot be released from the cell to the extracellular space due to the pH dependent binding. Then, the cells were chased for 30 minutes by changing pH to 7.4 by replacing medium. The amount of labeled antibodies accumulated in the cells after 0 and 30 minutes of chase was calculated by determining the median value of fluorescent intensity of each cell.

Fig 5 shows that more fluorescent signal could be detected in rbIgG than that of hlIgG1-labeled cells due to the different labeling efficiencies of IgGs. After 30 minutes of chase, significantly less rbIgG, as well as hlIgG can be detected in macrophages and the relative fluorescence intensity decreased similarly to about 60% in both cases (Fig 5).

Our data shows no difference in the recycling rate of rbIgG and hlIgG1 in rabbit macrophages supporting our SPR data, that rbFcRn can bind hlIgG1 as effectively as rbIgG.

These data confirm the results of historic FcRn-related papers that reported 6.0 and 5.0 day long half-lives of rabbit and human 7S gamma globulin (which refers to IgG), respectively, in rabbits [24–26].
Conclusions
Transplacental IgG transport in rabbits indicate that it occurs in a similar exposure time-window for offsprings as in humans, and rabbits as model, provide better statistical power. As we demonstrated by SPR experiments, as well as in FcRn-mediated recycling assay that rbfFcRn similarly binds hIgG1, and preferentially binds hIgG2, hIgG3 and hIgG4 over rblgG, rabbits can offer an alternative animal model to mouse and rats regarding IgG transport through the placenta. Our dataset also suggest that the hIgG producer rabbits would be fully functional regarding FcRn-mediated functions including maternal IgG transport, IgG protection and antigen presentation in case of antigen-IgG immune complexes.

Supporting information
S1 Fig. The raw, unadjusted source image corresponding to Fig 2A. (TIF)
S2 Fig. The raw, unadjusted source image corresponding to Fig 2B. (TIF)

Acknowledgments
We are grateful to József Kozma, Róbert János Berky and Tamás Schäfer (Gedeon Richter Plc, Budapest, Hungary) for their help in performing the SEC analyses. We thank Sally E. Ward (UT Southwestern Medical Center, Dallas, TX, USA) for providing the soluble hFcRn preparation used as a control in our experiments. We also thank Károly Liliom for his help in SPR data analyses and for valuable discussions.

Author Contributions
Conceptualization: László Hiripi, Balázs Bender, Imre Kacskovics, Attila Iliás.
Data curation: Bence Szikora, László Hiripi.
Formal analysis: Bence Szikora.
Funding acquisition: Imre Kacskovics.
Investigation: Bence Szikora, László Hiripi, Balázs Bender, Attila Iliás.
Methodology: Bence Szikora, László Hiripi, Balázs Bender, Attila Iliás.
Project administration: Attila Iliás.
Supervision: Imre Kacskovics, Attila Iliás.
Validation: László Hiripi, Imre Kacskovics, Attila Iliás.
Visualization: Bence Szikora.
Writing – original draft: Bence Szikora, László Hiripi, Attila Iliás.
Writing – review & editing: Imre Kacskovics, Attila Iliás.

References
1. Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature. 1989; 337 (6203):184–7. https://doi.org/10.1038/337184a0 PMID: 2911353.
2. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7 (9):715–25. https://doi.org/10.1038/nri2155 PMID: 17703228.
3. Baker K, Rath T, Pyzik M, Blumberg RS. The Role of FcRn in Antigen Presentation. Frontiers in immunology. 2014; 5:408. https://doi.org/10.3389/fimmu.2014.00408 PMID: 25221553.

4. Schneider Z, Jani PK, Szikora B, Vehg A, Kovacs D, Ilia A, et al. Overexpression of Bovine FcRn in Mice Enhances T-Dependent Immune Responses by Amplifying T Helper Cell Frequency and Germinal Center Enlargement in the Spleen. Frontiers in immunology. 2015; 6:357. https://doi.org/10.3389/fimmu.2015.00357 PMID: 26257730.

5. Cervenak J, Kurrle R, Kascikovics I. Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity. Immunological reviews. 2015; 268(1):269–87. https://doi.org/10.1111/1600-065X.12364 PMID: 26497527.

6. Kim JK, Tsen MF, Ghetie V, Ward ES. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol. 1994; 24(3):542–8. https://doi.org/10.1002/eji.1830240308 PMID: 8125126.

7. Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry. 1995; 34(45):14649–57. PMID: 7578107.

8. Rodewald R. pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol. 1976; 71(2):666–9. PMID: 11223.

9. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature. 1994; 372(6504):379–83. https://doi.org/10.1038/372379a0 PMID: 7969498.

10. Martin WL, West AP Jr., Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001; 7(4):867–77. PMID: 11336709.

11. West AP Jr., Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(s). Biochemistry. 2000; 39(32):9698–708. PMID: 10937386.

12. Huber AH, Kelley RF, Gastinel LN, Bjorkman PJ. Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol Biol. 1993; 230(3):1077–83. https://doi.org/10.1006/jmbi.1993.1220 PMID: 8478919.

13. Martin WL, Bjorkman PJ. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry. 1999; 38(39):12639–47. PMID: 10504233.

14. Sanchez LM, Penny DM, Bjorkman PJ. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry. 1999; 38(29):9471–6. https://doi.org/10.1021/bi9907330 PMID: 10413524.

15. Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. mAbs. 2015; 7(2):331–43. https://doi.org/10.1080/19420862.2015.1008353 PMID: 25658443.

16. Popov S, Hubbard JG, Kim J, Ober B, Ghetie V, Ward ES. The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Mol Immunol. 1996; 33(6):521–30. PMID: 8700168.

17. Brambell FWR. The transmission of passive immunity from mother to young. Amsterdam, New York,: North-Holland Pub. Co.; American Elsevier; 1970. xvi, 385 p. p.

18. Smith AE, Schechtman AM. Significance of the rabbit yolk sac: A study of the passage of heterologous proteins from mother to embryo. Dev Biol. 1962; 4:339–60. PMID: 13914130.

19. Bowman CJ, Breslin WJ, Connor AV, Martin PL, Moffat GJ, Sivaraman L, et al. Placental transfer of Fc-containing biopharmaceuticals across species, an industry survey analysis. Birth Defects Res B Dev Reprod Toxicol. 2013; 98(6):459–85. https://doi.org/10.1002/bddr.21089 PMID: 24391099.

20. DeSesso JM, Williams AL, Ahuja A, Bowman CJ, Hutt ME. The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. Crit Rev Toxicol. 2012; 42(3):185–210. https://doi.org/10.3109/10408444.2011.653487 PMID: 22348352.

21. Pentus N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009; 86(4):328–44. https://doi.org/10.1002/bddr.20201 PMID: 19626656.

22. Martin PL, Weinbauer GF. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions. Int J Toxicol. 2010; 29(6):552–68. https://doi.org/10.1177/1091581810378896 PMID: 20926830.

23. Martin PL, Zhou Z, van den Bulck K, Kwok D, Powers G, Jiao Q, et al. Pharmacology and placental transfer of a human alphav integrin monoclonal antibody in rabbits. Birth Defects Res B Dev Reprod Toxicol. 2010; 89(2):116–23. https://doi.org/10.1002/bddr.20232 PMID: 20151458.

24. Spiegelberg HL, Weigle WC. The Catabolism of Homologous and Heterologous 7s Gamma Globulin Fragments. J Exp Med. 1965; 121:323–38. PMID: 14271318.
25. Sabiston BH, Rose JE. Effect of cold exposure on the metabolism of immunoglobulins in rabbits. Journal of immunology. 1976; 116(1):106–11. PMID: 1245734.

26. Kobayashi Y, Kobayashi N, Minaga T, Aihara M, Shigematsu A. The metabolism and kinetics of 125I-labeled human intravenous IgG preparation (C-425) in rats and rabbits. I. Blood clearance, excretion into urine and feces, and brain uptake. European journal of drug metabolism and Pharmacokinetics. 1989; 14(1):35–42. PMID: 2759132.

27. Kuo TT, Aveson VG. Neonatal FC receptor and IgG-based therapeutics. mAbs. 2011; 3(5):422–30. https://doi.org/10.4161/mabs.3.5.16983 PMID: 22048693.

28. Catunda Lemos AP, Cervenak J, Bender B, Hoffmann OI, Baranyi M, Kerekés A, et al. Characterization of the rabbit neonatal FC receptor (FcRn) and analyzing the immunophenotype of the transgenic rabbits that overexpresses FcRn. PLoS One. 2012; 7(1):e28869. https://doi.org/10.1371/journal.pone.0028869 PMID: 22247762.

29. Gaton E, Wolman M. Macrophage activation in the prevention or regression of atherosclerosis. The Healing and Scarring of Atheroma: Springer; 1984. p. 15–36.

30. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9(7):676–82. https://doi.org/10.1038/nmeth.2274 PMID: 22743772.

31. Gates FT 3rd, Coligan JE, Kindt TJ. Complete amino acid sequence of rabbit beta 2-microglobulin. Biochemistry. 1979; 18(11):2267–72. PMID: 87220.

32. Nicholas K, Nicholas HJ. GeneDoc: a tool for editing and annotating multiple sequence alignments. 1997. Distributed by the author.

33. Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry. 2006; 45(15):4983–90. https://doi.org/10.1021/bi052628y PMID: 16605266.

34. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol. 1997; 15(7):637–40. https://doi.org/10.1038/nbt0797-637 PMID: 921965.

35. Kaczewikovics I, Kis Z, Mayer B, West AP Jr., Tiongo NE, Tilahun M, et al. FcRn mediates elongated serum half-life of human IgG in rabbit. Int Immunol. 2006; 18(4):525–36. https://doi.org/10.1093/intimm/dxh393 PMID: 16481343.

36. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001; 13(12):1551–9. PMID: 11717196.

37. Wang X, McKay P, Yee LT, Dutina G, Hass PE, Nijem I, et al. Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data. mAbs. 2017; 9(2):319–32. https://doi.org/10.4161/mabs.2001487.

38. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A. 2004; 101(26):9763–8. https://doi.org/10.1073/pnas.0403235101 PMID: 15210944.

39. Andersen JT, Dee Qian J, Sandlie I. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol. 2006; 36(11):3044–51. https://doi.org/10.1002/eji.200636556 PMID: 17048273.

40. Andersen JT, Daba MB, Berntzen G, Michaelson TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal FC receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem. 2010; 285(7):4826–36. https://doi.org/10.1074/jbc.M109.081828 PMID: 20018655.

41. Meads TJ, Wild AE. Evidence that Fc gamma receptors in rabbit yolk sac endoderm do not depend upon an acid pH to effect IgG binding and transcytosis in vitro. Placenta. 1994; 15(5):525–39. PMID: 7997452.
during organogenesis to late gestation. Birth Defects Res B Dev Reprod Toxicol. 2014; 101(2):178–88. https://doi.org/10.1002/bdrb.21105 PMID: 24753333.

45. Mohly M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007; 21(7):1387–94. https://doi.org/10.1038/sj.leu.2404683 PMID: 17410187.

46. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. Journal of immunology. 2007; 179(7):4580–8. PMID: 17878355.